Diabetes afflicts approximately 151 million people worldwide, with a estimated increase to 221 million by 2010. To date, no therapy for the treatment of diabetes complications is widely accepted. The enzyme dipeptidyl peptidase IV has shown promising results as a target for the treatment of type 2 diabetes. Structure studies of dipeptidyl peptidase IV in complex with inhibitor will be conducted to elucidate the details of enzyme-inhibitor interaction. The results will be used to identify the molecular basis of potency and selectivity of dipeptidyl peptidase IV and may lead to the discovery of pharmaceutical agents for the treatment of diabetes sufferers.
|Effective start/end date||19/01/06 → 31/03/10|
- Australian Research Council (ARC): AUD80,000.00
- Sanwa Kagaku Kenkyusho Co. Ltd.: AUD10,000.00